Fulvestrant ('Faslodex'): current and future role in breast cancer management.
Authors
Howell, AnthonyAffiliation
Cancer Research UK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK. maria.parker@christie-tr.nwest.nhs.ukIssue Date
2006-03
Metadata
Show full item recordAbstract
Fulvestrant ('Faslodex') is a new type of estrogen receptor antagonist with no agonist effects, that reduces cellular levels of both estrogen and progesterone receptors. Results from two Phase III trials showed that fulvestrant is at least as effective as the third-generation selective aromatase inhibitor anastrozole in postmenopausal women with advanced breast cancer following progression on antiestrogen therapy, indicating the potential for second-line fulvestrant in this setting. In clinical practice, fulvestrant is well tolerated, with good rates of clinical benefit observed as first-line therapy and following progression on prior endocrine agents. Other endocrine agents have been shown to have good clinical activity when resistance to fulvestrant has developed, showing that fulvestrant lacks cross-resistance with other treatments. Ongoing trials are investigating the efficacy of fulvestrant after failure on aromatase inhibitors and evaluating its use in combination with therapies that target growth factor receptor signaling pathways.Citation
Fulvestrant ('Faslodex'): current and future role in breast cancer management. 2006, 57 (3):265-73 Crit. Rev. Oncol. Hematol.Journal
Critical Reviews in Oncology/HematologyDOI
10.1016/j.critrevonc.2005.08.001PubMed ID
16473018Type
ArticleLanguage
enISSN
1040-8428ae974a485f413a2113503eed53cd6c53
10.1016/j.critrevonc.2005.08.001
Scopus Count
Collections
Related articles
- The future of fulvestrant ("Faslodex").
- Authors: Howell A
- Issue date: 2005
- Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
- Authors: Gradishar W
- Issue date: 2005 Jun
- Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
- Authors: Oakman C, Moretti E, Santarpia L, Di Leo A
- Issue date: 2011 Feb
- Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
- Authors: Vergote I, Robertson JF
- Issue date: 2004 Mar
- Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
- Authors: Mlineritsch B, Psenak O, Mayer P, Moik M, Namberger K, Hauser-Kronberger C, Greil R
- Issue date: 2007 Nov